摘要
免疫性血小板减少症(immune thrombocytopenia,ITP)是一种因血小板减少而引发一系列出血表现的自身免疫性疾病,发病机制尚不明确。其治疗以药物为主,一线药物有糖皮质激素和静脉滴注免疫球蛋白;二线治疗药物包括促血小板生成类药物、利妥昔单抗等;免疫抑制剂及脾切术需要严格掌握适应证;在临床试验中的新型药物包括脾脏酪氨酸激酶抑制剂、细胞因子等。联合治疗能进一步改善儿童慢性、难治性ITP的预后。该文对儿童ITP的治疗进展进行综述,为临床规范诊治提供参考依据。
Immune thrombocytopenia(ITP)is an autoimmune disease which causes a series of bleeding manifestations due to thrombocytopenia.The pathogenesis is not clear.The first-line drugs include glucocorticoids and intravenous immunoglobulin(IVIG).The second-line drugs include thrombopoietin,rituximab,etc.Immunosuppressants and splenectomy need to strictly grasp the indications.New drugs in clinical trials include spleen complex kinase inhibitors,cytokines,etc.Combined therapy will further improve the prognosis of chronic,refractory ITP in children.The review of the progress of ITP treatment in children provides a reference for clinical standard diagnosis and treatment.
作者
高健(综述)
徐刚(审校)
Gao Jian;Xu Gang(Department of Pediatric Hematology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处
《国际儿科学杂志》
2020年第11期787-791,共5页
International Journal of Pediatrics
